TITLE

Lipid Therapeutics Extends Colitis Program to U.S

AUTHOR(S)
Sheridan, Cormac
PUB. DATE
April 2013
SOURCE
BioWorld Today;4/11/2013, Vol. 24 Issue 69, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the extension of the ulcerative colitis treatment LT-02 program of Lipid Therapeutics GmbH in the U.S. Lipid Therapeutics plans to conduct Phase III program for LT-02, which is a controlled-release phosphatidylcholine formulation. The program is considered topical rather than systemic, which helps elevate blood lipids.
ACCESSION #
87637994

 

Related Articles

  • Positive Data Support New Drug Mechanism in Ulcerative Colitis. Sheridan, Cormac // BioWorld International;6/29/2011, Vol. 16 Issue 26, p4 

    The article reports on the new mode of action discovered in the LT-02, the ulcerative colitis treatment from Lipid Therapeutics GmbH during its Phase IIb trial. LT-02 is a controlled-release formulation of phospholipid phosphatidylcholine. Wolfgang Stremmel, founder of Lipid Therapeutics and...

  • Multicenter Randomized Controlled Trial for the Treatment of Ulcerative Colitis with a Leukocytapheresis Column. Sawada, Koji; Muto, Tetsuichiro; Shimoyama, Takashi; Satomi, Masamichi; Sawada, Toshio; Nagawa, Hirokazu; Hiwatashi, Nobio; Asakua, Hitoshi; Hibi, Toshifumi // Current Pharmaceutical Design;Feb2003, Vol. 9 Issue 4, p307 

    Background The administration of steroids is not always effective for the treatment of ulcerative colitis (UC). Their long-term use often causes adverse effects which sometimes result in their stoppage and acute exacerbation. Therefore, an alternative treatment is necessary in order to decrease...

  • Lipid Therapeutics Extends Colitis Program to U.S. Sheridan, Cormac // BioWorld International;4/17/2013, Vol. 18 Issue 16, p4 

    The article focuses on the plan of biotechnology firm Lipid Therapeutics GmbH to extend its pivotal program for its ulcerative colitis treatment LT-02 into the U.S. The U.S. Food and Drug Administration (FDA) issued an investigational new drug grant to Lipid Therapeutics, which will allow the...

  • LIPID THERAPEUTICS & NESTLÉ HEALTH SCIENCE PARTNER.  // Worldwide Biotech;Nov2015, Vol. 27 Issue 11, p7 

    The article reports that biopharmaceutical company Lipid Therapeutics GmbH has partnered with health-science company Nestlé Health Science SA. It states that the partnership aimed for exclusive rights to LT-02 compound (phosphatidylcholine) of Lipid which is used to treat patients with...

  • PHARMA: CLINIC ROUNDUP.  // BioWorld Today;1/9/2014, Vol. 25 Issue 6, p12 

    The article offers information on Phase III trials of vedolizumab drug from Takeda Pharmaceutical Co. Ltd. for the treatment of Crohn's disease and ulcerative colitis.

  • Adsorptive Granulocyte/Monocyte Apheresis for the Mai ntenance of Remission in Patients with Ulcerative Colitis: A Prospective Randomized, Double Blind, Sham-Controlled Clinical Trial. Fukunaga, Ken; Yokoyama, Yoko; Kamokozuru, Koji; Nagase, Kazuko; Nakamura, Shiro; Miwa, Hiroto; Matsumoto, Takayuki // Gut & Liver;Oct2012, Vol. 6 Issue 4, p427 

    Background/Aims: Weekly granulocyte/monocyte adsorption (GMA) to deplete elevated and activated leucocytes should serve as a non-pharmacological intervention to induce remission in patients with ulcerative colitis (UC). This trial assessed the efficacy of monthly GMA as a maintenance therapy to...

  • Ulcerative Colitis Global Clinical Trials Review, Q2 2011.  // Biomedical Market Newsletter;9/26/2011, Vol. 21, p1138 

    The article focuses on the report "Ulcerative Colitis Global Clinical Trials Review for the second quarter of 2011," provided by the GlobalData in the U.S. It states that the report offers elemental information and data on the clinical trials of key drugs for the treatment of ulcerative colitis....

  • Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled Phase 2 dose-ranging study.  // Inflammatory Bowel Disease Monitor;2012, Vol. 13 Issue 2, p67 

    This was a dose-ranging, Phase II study of a new formulation of vedolizumab in patients with a confirmed diagnosis of ulcerative colitis. This formulation of the a4β7 integrin blocker was developed to reduce immunogenicity. Significantly more vedolizumab than placebo recipients achieved a...

  • First Multicenter Study of Modified Release Phosphatidylcholine 'LT-02' in Ulcerative Colitis: A Randomized, Placebo-Controlled Trial in Mesalazine-Refractory Courses. Karner, Max; Kocjan, Andreas; Stein, Juergen; Schreiber, Stefan; von Boyen, Georg; Uebel, Peter; Schmidt, Carsten; Kupcinskas, Limas; Dina, Ion; Zuelch, Frank; Keilhauer, Gerhard; Stremmel, Wolfgang // American Journal of Gastroenterology;Jul2014, Vol. 109 Issue 7, p1041 

    OBJECTIVES:Phosphatidylcholine is a key component of the mucosal barrier. Treatment with modified release phosphatidylcholine aims to improve the impaired barrier function. The primary objective is to evaluate the efficacy of LT-02, a newly designed modified release phosphatidylcholine formula,...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics